Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 3Neoplasms 2Colorectal Neoplasms 2Liver Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Digestive System Neoplasms 1Desmoid Tumors 1Adrenocortical Carcinoma 1

Interventions

lutetium Lu 177 dotatate 2pasireotide 1copper dotatate CU-64 1amino-acid, glucose, and electrolyte solution 1abemaciclib 1Temozolomide 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Oxaliplatin 1Octreotide 1Nivolumab 1Lutetium-177 1Lutetium 1Leucovorin 1Ipilimumab 1Folfox protocol 1Fluorouracil 1Everolimus 1E-7386 1Capecitabine 1177Lu-octreotide, DOTA(0)-Tyr(3)- 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gastro-enteropancreatic neuroendocrine tumor × E-7386 × Clear all
NCT03833700 2026-02-27

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Eisai Inc.

Phase 1 Active not recruiting
70 enrolled
EndocrineGastrointestinalNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Desmoid Tumors, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡